Anne Armstrong

12.8k total citations · 3 hit papers
118 papers, 5.2k citations indexed

About

Anne Armstrong is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Anne Armstrong has authored 118 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Oncology, 55 papers in Pulmonary and Respiratory Medicine and 31 papers in Genetics. Recurrent topics in Anne Armstrong's work include Advanced Breast Cancer Therapies (40 papers), PARP inhibition in cancer therapy (23 papers) and BRCA gene mutations in cancer (20 papers). Anne Armstrong is often cited by papers focused on Advanced Breast Cancer Therapies (40 papers), PARP inhibition in cancer therapy (23 papers) and BRCA gene mutations in cancer (20 papers). Anne Armstrong collaborates with scholars based in United Kingdom, United States and France. Anne Armstrong's co-authors include Seock‐Ah Im, Binghe Xu, Nadine Tung, Pierfranco Conté, Norikazu Masuda, Mark E. Robson, Elżbieta Senkus, Suzette Delaloge, Susan M. Domchek and Carsten Goessl and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Anne Armstrong

110 papers receiving 5.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

2017 2.2k citations Mark E. Robson, Seock‐Ah Im et al. New England Journal of Medicine profile →
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

2019 497 citations Mark E. Robson, Nadine Tung et al. Annals of Oncology profile →
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

2018 460 citations Sylvia Adams, Sherene Loi et al. Annals of Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Anne Armstrong	3.5k	1.8k	1.5k	1.3k	1.1k	118	5.2k
David W. Cescon	2.9k 0.8×	1.8k 1.0×	1.2k 0.8×	1.4k 1.1×	632 0.6×	169	5.6k
Alison L. Hannah	2.5k 0.7×	2.5k 1.4×	1.2k 0.8×	763 0.6×	665 0.6×	122	4.9k
Susana Banerjee	3.6k 1.0×	2.1k 1.2×	852 0.6×	1.0k 0.8×	1.0k 0.9×	307	7.0k
Frances A. Collichio	3.1k 0.9×	1.4k 0.8×	562 0.4×	1.4k 1.0×	1.0k 0.9×	100	4.6k
Giampaolo Bianchini	3.9k 1.1×	2.4k 1.4×	1.4k 0.9×	2.3k 1.7×	367 0.3×	139	6.5k
Ruth Plummer	3.4k 1.0×	3.3k 1.9×	1.1k 0.8×	688 0.5×	379 0.3×	230	6.0k
Joyce F. Liu	3.9k 1.1×	2.8k 1.6×	703 0.5×	903 0.7×	659 0.6×	184	6.4k
Glen J. Weiss	3.1k 0.9×	4.2k 2.4×	1.9k 1.3×	1.9k 1.5×	419 0.4×	209	7.9k
Stanley B. Kaye	2.5k 0.7×	3.2k 1.8×	627 0.4×	949 0.7×	1.2k 1.0×	102	6.1k
David S.P. Tan	2.5k 0.7×	2.2k 1.3×	563 0.4×	1.5k 1.1×	664 0.6×	181	5.1k

Countries citing papers authored by Anne Armstrong

Since Specialization

Citations

This map shows the geographic impact of Anne Armstrong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Armstrong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Armstrong more than expected).

Fields of papers citing papers by Anne Armstrong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Armstrong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Armstrong. The network helps show where Anne Armstrong may publish in the future.

Co-authorship network of co-authors of Anne Armstrong

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Armstrong. A scholar is included among the top collaborators of Anne Armstrong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Armstrong. Anne Armstrong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Michael, Sarah, et al.. (2026). Distant recurrence and margin involvement in invasive breast cancer. British Journal of Cancer. 134(5). 772–780.

Weaver, Jamie, et al.. (2025). Low-risk febrile neutropenia: does combined chemotherapy/immune checkpoint inhibitor necessitate a change in approach?. Supportive Care in Cancer. 33(2). 112–112. 1 indexed citations

Hamilton, Erika, Timothy Pluard, Judy S. Wang, et al.. (2024). H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).. Journal of Clinical Oncology. 42(16_suppl). 1015–1015. 4 indexed citations

Fehm, Tanja, Francesco Cottone, Fabrice André, et al.. (2024). Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial. The Lancet Oncology. 25(5). 614–625. 16 indexed citations

Robson, Mark E., Seock‐Ah Im, Elżbieta Senkus, et al.. (2023). OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. European Journal of Cancer. 184. 39–47. 54 indexed citations

Senkus, Elżbieta, Suzette Delaloge, Susan M. Domchek, et al.. (2023). Olaparib efficacy in patients with germline BRCA ‐mutated, HER2 ‐negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial. International Journal of Cancer. 153(4). 803–814. 16 indexed citations

Fehm, Tanja, Fabrice André, Ian E. Krop, et al.. (2023). 186O Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2–positive (HER2+) metastatic breast cancer (mBC). ESMO Open. 8(1). 101375–101375. 4 indexed citations

Wildiers, Hans, Anne Armstrong, Eveline Cuypere, et al.. (2023). Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial. Clinical Cancer Research. 30(3). 532–541. 12 indexed citations

Behrouzi, Roya, Anne Armstrong, & Sacha J. Howell. (2023). CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis. Breast Cancer Research and Treatment. 202(1). 83–95. 3 indexed citations

10.

Lindeman, Geoffrey J., Tharu M. Fernando, Rebecca Bowen, et al.. (2022). VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results. Clinical Cancer Research. 28(15). 3256–3267. 49 indexed citations

11.

Wysocki, Oskar, Markel Vigo, Anne Armstrong, et al.. (2022). Assessing the communication gap between AI models and healthcare professionals: Explainability, utility and trust in AI-driven clinical decision-making. Artificial Intelligence. 316. 103839–103839. 61 indexed citations

12.

Robson, Mark E., Nadine Tung, Pierfranco Conté, et al.. (2019). OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology. 30(4). 558–566. 497 indexed citations breakdown →

13.

Robson, Mark E., Kathryn J. Ruddy, Seock‐Ah Im, et al.. (2019). Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer. 120. 20–30. 57 indexed citations

14.

Hamilton, Erika, Manish R. Patel, Anne Armstrong, et al.. (2018). A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer. Clinical Cancer Research. 24(15). 3510–3518. 67 indexed citations

15.

Adams, Sylvia, Sherene Loi, Deborah Toppmeyer, et al.. (2017). Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.. Journal of Clinical Oncology. 35(15_suppl). 1088–1088. 55 indexed citations

16.

Robson, Mark E., Seock‐Ah Im, Elżbieta Senkus, et al.. (2017). Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New England Journal of Medicine. 377(6). 523–533. 2156 indexed citations breakdown →

17.

Loncaster, J., Anne Armstrong, Sacha J. Howell, et al.. (2017). Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK. European Journal of Surgical Oncology. 43(5). 931–937. 50 indexed citations

18.

Fleeman, Nigel, A Bagust, Angela Boland, et al.. (2011). Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. Health Technology Assessment. 15(42). 1–93, iii. 50 indexed citations

19.

Armstrong, Anne. (2002). The Quiet Revolution: Reference Services in Public Libraries. Australasian public libraries and information services. 15(3). 104. 1 indexed citations

20.

Armstrong, Anne, et al.. (2002). Immunization with a Recombinant Adenovirus Encoding a Lymphoma Idiotype: Induction of Tumor-Protective Immunity and Identification of an Idiotype-Specific T Cell Epitope. The Journal of Immunology. 168(8). 3983–3991. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact